Publications by authors named "G Thabut"
Objectives: Data on the economic consequences of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are scarce in Europe. We aimed to estimate the total direct costs attributable to SLE and LN in France, at the nationwide level.
Methods: Patients with SLE and LN were identified in the French nationwide health insurance database (SNDS).
Introduction: From 2018 single inhaler triple therapy (SITT) became available in France to treat moderate-to-severe chronic obstructive pulmonary disease (COPD). Given its simplified inhaler use compared with multiple inhaler triple therapy (MITT), this therapeutic option has the potential to offer benefit in terms of improved persistence and adherence. Given the lack of real-world evidence of the effectiveness of triple therapy, this study was designed to evaluate the use of MITT and SITT in France and compare persistence.
View Article and Find Full Text PDFPurpose: Data on severe non-eosinophilic asthma are scarce. Moreover, as compared with eosinophilic asthma, non-eosinophilic asthma less frequently benefits from the latest therapeutic advances. This study aimed to highlight differences between non-eosinophilic and eosinophilic asthma as they may help the development of new therapeutic agents.
View Article and Find Full Text PDFBackground: Data on health care consumption and costs of asthma in the French population are scarce.
Objectives: The study objective was to describe the burden of asthma according to GINA treatment steps in the CONSTANCES cohort.
Methods: Data from 162,725 participants included between 2012 and 2019 were extracted.
Article Synopsis
- The COVID-19 pandemic sparked a massive research effort in academia and industry, although some of it was redundant and poorly coordinated on national and international levels.
- Regulatory changes and the digitization of processes helped make clinical trials more accessible to patients, particularly in the UK where a single platform trial optimized resource use.
- Despite highlighting weaknesses in France's clinical research organization, such as funding issues and data sharing reluctance, the crisis demonstrated the adaptability of stakeholders and improved processes for future therapeutic innovations.